Background: IL-33 plays an important role in the development of experimental asthma. Objective: We sought to study the role of the IL-33 receptor suppressor of tumorigenicity 2 (ST2) in the persistence of asthma in a mouse model. Methods: We studied allergen-induced experimental asthma in ST2 knockout (KO) and wild-type control mice. We measured airway hyperresponsiveness by using flexiVent; inflammatory indices by using ELISA, histology, and real-time PCR; and type 2 innate lymphoid cells (ILC2s) in lung single-cell preparations by using flow cytometry. Results: Airway hyperresponsiveness was increased in allergen-treated ST2 KO mice and comparable with that in allergen-treated wild-type control mice. Peribronchial and perivascular inflammation and mucus production were largely similar in both groups. Persistence of experimental asthma in ST2 KO mice was associated with an increase in levels of thymic stromal lymphopoietin (TSLP), IL-9, and IL-13, but not IL-5, in bronchoalveolar lavage fluid. Expectedly, ST2 deletion caused a reduction in IL-13 1 CD4 T cells, forkhead box P3-positive regulatory T cells, and IL-5 1 ILC2s. Unexpectedly, ST2 deletion led to an overall increase in innate lymphoid cells (CD45 1 lin 2 CD25 1 cells) and IL-13 1 ILC2s, emergence of a TSLP receptor-positive IL-9 1 ILC2 population, and an increase in intraepithelial mast cell numbers in the lung. An anti-TSLP antibody abrogated airway hyperresponsiveness, inflammation, and mucus production in allergen-treated ST2 KO mice. It also
Type 2 innate lymphoid cells (ILC2s) represent an important group of type 2 immune cells. 1, 2 They are regulated by many growth factors. IL-33 is an important growth factor for ILC2s, especially lung ILC2s, 1, 2 and promotes their differentiation, maturation, and type 2 cytokine expression. IL-33 signals through its receptor, suppressor of tumorigenicity 2 (ST2), also known as T1/ST2L.
3 ST2 signaling is critically important for IL-5 induction in T H 2 cells and is required for T H 2 memory. 4 ST2 signaling regulates many other cells, including regulatory T (Treg) cells, 5 dendritic cells, 6 mast cells, 7 basophils, 8 eosinophils, 9 and macrophages. 10 By regulating so many immune cells, the IL-33/ST2 axis plays a seminal role in host defense and allergic and chronic inflammatory diseases. 11 The role of ST2 was previously investigated in various models of experimental asthma. [12] [13] [14] [15] [16] [17] Some studies reported a complete or substantial resolution of airway hyperreactivity, inflammation, goblet cell hyperplasia, and other features of asthma. [12] [13] [14] [15] A few studies observed persistence of experimental asthma in ST2 knockout (KO) mice. 16, 17 Complete resolution of experimental asthma and lung inflammation was observed only when all 3 type 2-inducing epithelial cytokines, IL-25, IL-33 and thymic stromal lymphopoietin (TSLP), or their receptors were blocked. 17 Interestingly, most of these studies were performed in acute asthma models or in a model of chronic allergen exposure in which outcomes were measured within 1 to 3 days of the last allergen exposure.
We developed a mouse model in which experimental asthma persists for more than 6 months after the last allergen exposure. 18, 19 The persistence of experimental asthma in this model was dependent on ILC2s but not T cells, although the latter contributed to the magnitude of airway inflammation. We investigated whether ST2 played an essential role in this chronic asthma model. 
METHODS
The protocol for this study was approved by the National Jewish Health Institutional Animal Care and Use Committee. We obtained ST2 KO mice from Dr Andrew McKenzie (Cambridge, United Kingdom). 12 These mice were backcrossed to BALB/C mice for more than 8 generations. We used BALB/C mice as wild-type (WT) controls (Jackson Laboratory, Bar Harbor, Me).
Mucosal sensitization of mice
The allergen extract used in this experiment was a mixture of 3 allergens: dust mite (Dermatophagoides farinae), ragweed (Ambrosia artemisiifolia), and Aspergillus fumigatus (Greer Laboratories, Lenoir, NC). We used the following protein concentrations of the allergen extracts: D farina, 5 mg (LPS content, 3-35 EU by means of LAL assay); ragweed, 50 mg (LPS content, 5 EU); and Aspergillus species, 5 mg (LPS content, 0.1 EU). The allergen dose was based on the results of a survey of previous publications (a total of 7 publications) indicating successful sensitization and elicitation of allergic inflammation in the lungs. 18 This allergen mixture was delivered intranasally in 15-mL aliquots in saline. Chronic experimental asthma was developed by means of intranasal delivery of the triple-allergen mixture twice a week for 6 consecutive weeks in female mice 8 to 12 weeks of age, as described previously. 18, 19 A timeline of manipulations and interventions for the chronic asthma protocol with allergens is shown in Fig 1, A. 
Antibody, pharmacologic, and genetic interventions
For TSLP blockade experiments, an anti-TSLP antibody (#MAB555; R&D Systems, Minneapolis, Minn; 20 mg/20 mL in saline administered intranasally) was delivered for 3 consecutive days 3 days before analysis in week 10. An isotype rat IgG 2a (#MAB006) antibody was used as a control.
Airway hyperreactivity measurement
Measurement methodologies have been explained in depth elsewhere. 18 Briefly, mice were anesthetized with ketamine (180 mg/kg), xylazine (9 mg/kg), and acepromazine (4 mg/kg). After the loss of the foot-pad pinch reflex, a tracheotomy was performed, and the mouse was attached through an 18-gauge cannula to a small-animal ventilator with a computercontrolled piston (flexiVent Fx; SCIREQ, Montreal, Quebec, Canada).
After performing initial calibrations (cylinder pressure channel and nebulizer calibration), we conducted dynamic tube calibration and used a default program called QuickPrime 3 (version 7) for measurement of airway resistance in response to methacholine. This program uses prime perturbations, which are a family of complex forced oscillation perturbations at a frequency greater than and less than the subject's ventilation frequency . The amplitude of the oscillatory signal is preset to a volume that is slightly smaller than the subject's tidal volume (0.2 mL). Volume and pressure signal are recorded during a measurement, and the flow signal is derived from the volume. The foregoing allows calculation of Newtonian resistance, tissue damping, tissue elastance, and hysteresivity. Resistance measurements were taken to establish the baseline for total lung resistance and at each methacholine dose. Group averages were expressed as the fold increase over baseline resistance (mean 6 SEM).
Histology and immunofluorescence staining
Paraffin-embedded lungs were sectioned and stained with hematoxylin and eosin for morphometric analysis, periodic acid-Schiff for mucin staining, Masson trichrome for collagen deposition, and toluidine blue for mast cell staining. Sections for immunofluorescence staining were permeabilized with 0.01% saponin in PBS, blocked with 2% BSA, and stained with a primary antibody against mouse TSLP (rabbit polyclonal; #ab115700; Abcam, Cambridge, United Kingdom); visualized with an Alexa Fluor 594-conjugated secondary antibody, as described previously 19 ; and counterstained with 49-6-diamidino-2-phnylindole dihydrochloride for nuclear staining.
Images were acquired on a Nikon Eclipse TE2000-U microscope using 320 dry lenses at room temperature through a Diagnostics Instruments camera model #4.2 using Spot Software 5.0 (Diagnostic Instruments, Sterling Heights, Mich). Hematoxylin and eosin-stained sections were mounted with Permount Medium (Thermo Fisher Scientific, Waltham, Mass). Images were adjusted for brightness and contrast to improve viewing.
Lung digests
Lungs were perfused with saline, and single-cell suspensions of lung cells were acquired by using mechanical mincing of the lungs followed by digestion at 378C for 45 minutes in RPMI with 10% FBS, 1% penicillin/streptomycin, and collagenase Type I (1 mg/mL; #LS004197; Worthington Biochemical, Lakewood, NJ), as described previously. 19 Cell suspensions were agitated at room temperature for 10 minutes in RPMI with 100 U/mL DNAse I before filtration through 40-mm filters and red blood cell lysis. Single-cell suspensions were cultured subsequently in RPMI with 10% FBS and 1% penicillin/streptomycin at 378C in a CO 2 incubator overnight. The next day, cells were used for flow cytometric staining and analysis.
Flow cytometric analyses of innate lymphoid cells and T cells
We stained live cells first for cell-surface receptors. Then we fixed the cells with 4% paraformaldehyde for 15 minutes at 48C, washed them with staining buffer (PBS plus 1% BSA), and then incubated with permeabilization buffer (PBS [pH 7.4] plus 1% BSA plus 0.1% saponin) at 48C for 20 minutes. After centrifugation, we resuspended the cells in permeabilization buffer and incubated with antibodies against the intracellular proteins (cytokines and transcription factors) at 48C for 30 minutes. We washed the cells twice with the permeabilization buffer, resuspended in the staining buffer, and maintained at 48C until flow analysis. For intercellular cytokines, we added monensin (2 mmol/L) to the cells and cultured for 4 hours before staining. Most of the fluorophore-conjugated antibodies were purchased from BioLegend (San Diego, Calif) and some were purchased from eBioscience (San Diego, Calif) or R&D Systems, unless otherwise stated.
Mouse lung single-cell suspension was blocked with an anti-FcR blocking reagent (#130-092-575; Miltenyi Biotec, Bergisch Gladbach, Germany) before staining. #FAB10402A; R&D Systems), followed by Pacific blue-labeled lineage, FITC-conjugated anti-CD45.2, and PerCP-Cy5.5 conjugated anti-CD25 antibodies. PE/Cy7-conjugated anti-IL-13 antibody and PE-conjugated anti-forkhead box P3 (FoxP3) and PerCP-Cy5.5 conjugated anti-CD25 antibody, followed by APC-conjugated anti-CD4 and FITC-conjugated anti-CD45.2 antibody, were used for T-cell and FoxP3
1 Treg cell analysis. We performed routine 5-to 7-color flow cytometry. Because we studied more than 7 target molecules, we split the isolated lung cells into 2 or more samples (depending on the need). We used fluorophoreconjugated antibodies against CD45.2, the lineage cocktail, and CD25 to detect innate lymphoid cells (ILCs). Then we treated cells with 4 additional colormatched antibodies against the ILC2 markers KLRG1, TSLPR, ICOS, IL-17RB, IL-7RA, GATA-3, IL-5, IL-9, and IL-13, as appropriate for the experimental question. For controls, we used unstained cells and cells stained with an isotype control antibody. We performed simultaneous flow cytometry for fluorescence minus one. We used the following equipment: LSRII and LSRFortessa (BD Biosciences, San Jose, Calif).
Real-time PCR
Total RNA was isolated from frozen tissues by using TRIzol (Invitrogen), and cDNAwas synthesized with the Verso-cDNA Synthesis Kit (#AB-1453/B; (Fig 1, E) and perivascular (Fig 1, F) inflammation and goblet cell hyperplasia (Fig 1, G) in WT and ST2 KO mice. A, Allergen exposed; KO, ST2 knockout; S, saline exposed.
Thermo Fisher Scientific), according to the manufacturer's instructions, as described previously. 19 Gene-specific PCR products were amplified by using qPCR SYBR Green Rox mix (#AB-4162/B; Thermo Fisher Scientific) and primers outlined in Table E1 in this article's Online Repository at www.jacionline.org. Primers were designed with the Applied Biosystems 7000 Sequence Detection System software (Applied Biosystems, Foster City, Calif). Levels of target gene expression were normalized to levels of 18S ribosomal RNA expression by using the 2 2DDCt method.
ELISA for cytokines
Levels of TSLP (ELISA kit #88-7490-88; eBioscience), IL-9 (ELISA kit #88-8092-88; eBioscience), and IL-13 (ELISA kit #DY413-05; R&D Systems) in bronchoalveolar lavage (BAL) fluid were measured by means of ELISA, according to the manufacturer's instructions.
Statistical analyses
Statistical analyses were performed, and data figures were prepared with GraphPad Prism software (version 6; GraphPad Software, San Diego, Calif).
RESULTS

ST2 is not essential for the persistence of airway hyperreactivity in chronic experimental asthma
We examined the effect of germline deletion/KO of the IL-33 receptor ST2 on chronic experimental asthma in a mouse model. Mice were exposed intranasally to a combination of 3 allergens (dust mites, ragweed, and Aspergillus species) or saline twice a week for 6 weeks, rested for 3 weeks, and then subjected to measurements of airway hyperreactivity, inflammation, and tissue remodeling (Fig 1, A) . Allergen-exposed WT and KO mice showed a significant increase in airway resistance in response to methacholine when compared with saline-exposed mice (Fig 1, B) . There was no significant difference in airway hyperreactivity between WT and KO mice. Total numbers of cells in BAL fluid were increased significantly in allergen-treated WT mice compared with those in saline-treated mice (see Fig E1, A-C, in this article's Online Repository at www.jacionline.org). Allergen-treated ST2 KO mice had greater numbers of total BAL fluid cells compared with allergen-treated WT mice. Allergen-treated WT mice had increased numbers of neutrophils and eosinophils, which were absent in ST2 KO mice. Lung histology showed reduced levels of peribronchial and perivascular inflammation (Fig 1, E and F) in ST2 KO mice. However, levels of mucus-producing airway goblet cell hyperplasia (Fig 1, D and G) and airway remodeling/collagen deposition (see Fig E1, D-F) were similar in allergen-treated ST2 KO and WT mice. The foregoing findings indicate that many features of chronic experimental asthma, especially airway hyperreactivity and mucus production, persist in the absence of ST2.
IL-9
1 and IL-13 1 ILC2 numbers are increased in ST2 KO mice
Next we examined the effect of ST2 deletion on ILC2s in lung digests from study animals. The gating strategy for detection of The frequency of dead cells in gated live CD45 1 cells was approximately 7% in lung digests from both WT and KO mice (see Fig E2, A) . We identified ILCs as CD45 ) were increased in chronic experimental asthma compared with those in saline-treated control animals (Fig 2, A) , which confirmed our previous report. 19 Unexpectedly, total ILC numbers were even greater in ST2 KO mice compared with those in WT control animals in the chronic asthma model. This increase was observed not only with total ILCs but also with ILC2s carrying the specific markers KLRG1 (Fig 2, B) , TSLPR (Fig 2, C) , and ICOS but not IL-17RB (IL-25 receptor; see Fig E3 in this article's Online Repository at www.jacionline.org).
Next, we examined expression of type 2 cytokines by ILC2s. ST2 KO mice had greater numbers of IL-13
1 and IL-9 1 ILC2s compared with WT mice (Fig 2, D and E) . Interestingly, they had lower numbers of IL-5
1 ILC2s compared with WT mice (Fig 2, F) . Nonetheless, ST2 KO mice had increased numbers of IL-5
1 ILC2s when compared with saline-treated mice. Previously, we reported that this chronic asthma model was associated with increased numbers of CD4 T cells and CD4 1 natural regulatory T (nTreg) cells 18 and that CD4 T cells contributed to the magnitude of airway inflammation. 19 We examined the role of ST2 in this model. As expected, T H 2 cell numbers, as measured based on IL-13 1 CD4 T cells, and CD25
1
FoxP3
1 nTreg cell numbers were increased in the chronic asthma model (Fig 3, A and B) . ST2 deletion did not have any effect on numbers of these cell types in the setting of chronic experimental asthma. Interestingly, numbers of IL-13
1
CD4 T cells and CD25
1
FoxP3
1 nTreg cells were greater in saline-treated ST2 KO mice compared with those in saline-treated WT mice.
IL-9, IL-13, and TSLP levels are increased in the airways of ST2 KO mice
To establish the relevance of increased type 2 cytokine-positive ILC2s, we measured type 2 cytokine mRNA expression in the lung tissue and protein expression in BAL fluid. IL-13 and IL-9 levels were increased in the lung (see Fig E4, A and B, in this article's Online Repository at www.jacionline.org) and in BAL fluid from the chronic asthma model (Fig 3, C and D) . These levels were even greater in ST2 KO mice, which was in agreement with heightened IL-13
1 and IL-9 1 ILC2s in this group. The magnitude of the increase in IL-9 levels in BAL fluid from ST2 KO mice was remarkable. Even the saline-treated ST2 KO mice had greater baseline levels of IL-9. Among the epithelial cytokines that control tissue ILC2s, TSLP was shown previously to regulate T H 9 differentiation and IL-9 expression. We examined TSLP expression in lung tissue and BAL fluid. Both mRNA and protein expression of TSLP were increased in WT and ST2 KO mice from the chronic asthma model (Fig 3, E , and see Fig E4, C) . Levels paralleled IL-9 concentrations in BAL fluid The cytokines IL-13 (Fig 3, C) , IL-9 (Fig 3, D) , and TSLP (Fig 3, E) were assayed by means of ELISA. Each symbol represents a mouse. A, Allergen exposed; KO, ST2 knockout; S, saline exposed.
(ie, the TSLP level was greater in ST2 KO mice than in WT mice). Interestingly, saline-treated ST2 KO mice had increased TSLP levels in BAL fluid, suggesting that ST2 negatively regulated TSLP expression. We examined the source of TSLP in the lung. TSLP was primarily produced by airway epithelial cells (see Fig E5 in this article's Online Repository at www.jacionline. org). In accordance with TSLP levels in BAL fluid, TSLP expression was greater in ST2 KO mice. We also examined mRNA expression for IL-33, which was increased in the chronic asthma model (see Fig E4, D) . Interestingly, IL-33 mRNA expression was even greater in ST2 KO mice, suggesting the existence of a negative feedback inhibition in WT mice, loss of which caused an increase in IL-33 expression. IL-17A has been shown to be involved in some mouse models of experimental asthma. 20 We observed increased expression of mRNA for IL-17A and IL-17F in the chronic asthma model. ST2 KO mice did not affect mRNA for IL-17A but reduced mRNA expression for IL-17F (see Fig E4, E and F) .
Increased expression of intraepithelial mast cells and mucus in ST2 KO mice
IL-9 is known to induce mast cell hyperplasia. [21] [22] [23] Both IL-9 and IL-13 stimulate mucus production. 21 We examined mRNA expression of mast cell protease 1 (MCP1) and the mucus genes MUC5AC and MUC5B. Expression of mRNA for MCP1 and MUC5AC but not MUC5B was increased in ST2 KO mice compared with that seen in WT control mice in the chronic asthma model (Fig 4, A-C) . The result of mucus staining in ST2 KO mice is in agreement with MUC5AC data. Previously, we reported that chronic experimental asthma was associated with increased intraepithelial mast cells. 18 To validate the result of increased MCP1 mRNA expression, we examined intraepithelial mast cells. ST2 KO mice from the chronic asthma model expressed higher numbers of intraepithelial mast cells compared with WT mice (Fig 4, D and E) . The results in aggregate suggest that increased TSLP production in ST2 KO mice led to a cascade of events involving induction of IL-9
1 and IL-13 1 ILC2s and intraepithelial mast cells.
An anti-TSLP antibody induces resolution of experimental asthma in ST2 KO mice
To determine whether TSLP played a critical role in the persistence of experimental asthma in ST2 KO mice, we treated mice with an anti-TSLP antibody or isotype control antibody in week 10, 3 days before outcome measurements (Fig 5, A) . The anti-TSLP antibody significantly (P < .001) inhibited airway hyperreactivity, tissue inflammation, and mucus production compared with the isotype control antibody (Fig 5, B-G) . (Fig 4, A) and the mucin genes MUC5AC (Fig 4, B) and MUC5B (Fig 4, C) in lung tissue. mRNA expression was measured by using real-time PCR, and data were expressed in reference to the expression level of 18S ribosomal RNA. D, Representative image of toluidine-positive intraepithelial mast cells in lung tissue from an ST2 KO mouse with chronic experimental asthma. E, Comparison of intraepithelial mast cells between allergen-treated WT and ST2 KO mice. Results are shown as numbers of mast cells per millimeter of basement membrane (BM). A, Allergen exposed; KO, ST2 knockout; S, saline exposed.
TSLP blockade abrogates induction of IL-9
1 and IL-13 1 ILC2s and IL-9 and IL-13 expression in the airways
We examined the effect of the anti-TSLP antibody on ILC populations in the lung. TSLP blockade reduced the number of total ILCs (CD45 1 , Lin 2 , and CD25 1 ), KLRG1 1 ILC2s, TSLPR1 ILC2s, IL-9
1 ILC2s, and IL-13 1 ILC2s (Fig 6) . As anticipated, this treatment also reduced expression of TSLP, IL-9, and IL-13 in BAL fluid (Fig 7) .
Next, we studied the effect of the anti-TSLP antibody on mast cells. The MCP1 mRNA expression was significantly reduced in anti-TSLP-treated mice (see Fig E6, A, in this article's Online Repository at www.jacionline.org). There was a corresponding reduction in intraepithelial mast cell numbers in anti-TSLPtreated mice (Fig 7, D) . Periodic acid-Schiff staining of lung tissue showed inhibition of mucus production after anti-TSLP treatment (Fig 5, D) . An analysis of expression of mRNA for MUC5AC confirmed these data and showed significant inhibition of its expression after TSLP treatment (see Fig E6, B) .
DISCUSSION
The role of IL-33 and its receptor, ST2, has been studied previously in mouse models of experimental asthma. ST2 KO mice produced variable results depending on the mouse model used. ST2 KO mice showed inhibition of acute asthma in some Fig 5, D) production between anti-TSLP-and isotype antibody-treated ST2 KO mice (representative of 5 mice per group). E-G, Morphometric quantification of peribronchial (Fig 5, E) and perivascular (Fig 5, F) inflammation and goblet cell hyperplasia (Fig 5, G) in ST2 KO mice treated with anti-TSLP and isotype control antibody.
J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 3 models 12-15 but not in others. 16, 17 We developed a chronic model in which experimental asthma persists in the absence of allergen challenge for longer than 6 months. In a different model of experimental asthma in which sensitized mice were intratracheally challenged with Aspergillus fumigatus conidia, airway pathology and hyperreactivity persisted up to day 44. 24, 25 We believe that these chronic models more closely mimic human asthma because the latter persists without regard to allergen exposure.
In this article we showed that chronic experimental asthma persisted in ST2 KO mice. Airway hyperreactivity and mucus production persisted unabated. The absence of ST2 reduced the magnitude of airway inflammation. We showed that in the absence of ST2 signaling, there was a paradoxical increase in TSLP expression in airway epithelial cells, which led to an increase in IL-9
1 and IL-13 1 ILC2 numbers in the airways and an increase in mast cell numbers. We believe that the foregoing contributed to the persistence of experimental asthma. Inhibition of TSLP completely abrogated chronic experimental asthma, suggesting that TSLP played an essential role in the development of chronic experimental asthma in ST2 KO mice.
Previously, an IL-33-independent and IL-25-regulated subtype of ILC2s was reported by Huang et al. 26 These IL-25-dependent ST2
2 ILC2s were equally effective in mounting a type 2 immune response against parasitic infection. A TSLP-induced subtype of ILC2s, which functioned independently of IL-25 and IL-33, was identified initially in the skin. 27 This TSLP-dependent ILC2 population induced atopic dermatitis-like lesions in mice. A TSLP-dependent and IL-33-independent ILC2 population was also identified in the mouse lung after infection with respiratory syncytial virus. 28 The foregoing studies suggest that TSLP-dependent ILC2s can independently induce a type 2 inflammatory phenotype in the mouse model.
Many cells produce IL-33 and TSLP, but the primary source for these cytokines in the lung is airway epithelial cells. 29 The endogenous mechanism of IL-33 and TSLP production is less known. Our results suggest that IL-33 signaling through ST2 triggers a negative feedback inhibition of IL-33. In the absence of ST2, this negative feedback is lost. Consequently, IL-33 production is increased in ST2 KO mice. We believe that TSLP and IL-33 are coregulated. Increased expression of IL-33 also leads to heightened production of TSLP in ST2 KO mice. Coregulation of IL-33 and TSLP has been reported previously. Many environmental agents simultaneously induce IL-33 and TSLP. 30 Previous studies demonstrated a positive regulation of TSLP by IL-33. IL-33 induced TSLP in human nasal epithelial cells in vitro 30 and in mouse airways in vivo. 31 Because we observed increased TSLP and IL-33 levels in ST2 KO mice, we speculate that this coregulation was the result of activation of a common signaling/transcriptional mechanism or mechanisms not involving ST2. We examined the mechanism by which TSLP promotes the persistence of experimental asthma in ST2 KO mice. TSLP increased numbers of IL-9
1 and IL-13 1 ILC2s but not IL-5 1 ILC2s and expression of IL-9 protein in the lung. These result suggests that TSLP was important for IL-9 induction in ST2 KO mice.
TSLP was previously shown to induce T H 9 and increase IL-9 production. 32, 33 TSLP induced signal transducer and activator of transcription 5, which directly bound to the IL-9 promoter and facilitated its transcription. 32 An anti-IL-9 antibody abolished airway inflammation associated with TSLP overexpression. Based on these studies, IL-9 is considered a critical effector molecule for TSLP-induced airway inflammation. IL-9 was shown previously to induce experimental asthma in mice. 34 The effect of IL-9 was considered to be mediated by IL-13. Allergen challenge induced IL-9 in airway tissue from asthmatic patients, suggesting an association with human asthma. 35 The effect of IL-9 on goblet cell function and mucus production is complex. IL-9 did not directly induce goblet cell proliferation or mucus production from human airway epithelial cells. 36 The effect of IL-9 on mucus production in mice was mixed. IL-9 deficiency was associated with defective goblet cell hyperplasia and mucus production in parasite-induced pulmonary granulomas in mice. 22 On the other hand, IL-9 was redundant for mucus production, as well as airway inflammation and hyperreactivity, in an allergen-induced asthma model. 37 These studies suggest that the effect of IL-9 on allergic inflammation varies depending on the experimental model. ILC2-derived IL-9 was shown previously to exert an autocrine effect and amplified IL-13 production, which sustained inflammation by inducing IL-33 and TSLP production by airway epithelial cells. 38 Thus IL-9 could have contributed to the sustenance of inflammation in ST2 KO mice.
TSLP-deficient mice had impaired airway inflammation and mucus production in an allergen-induced asthma model. 39, 40 Conversely, lung-specific overexpression of TSLP caused airway hyperreactivity, type 2 inflammation, goblet cell hyperplasia, and subepithelial fibrosis. The foregoing findings suggest an important role for TSLP in multiple aspects of asthma pathology, including mucus production. We observed increased mucus production and heightened expression of mRNA for MUC5AC in ST2 KO mice. The anti-TSLP antibody abrogated mucus production. We believe that TSLP directly induced mucus production in ST2 KO mice. IL-9 is a known mast cell growth factor. 21 It stimulated mast cell development from stem cells in vitro. IL-9 overexpression caused mast cell hyperplasia in vivo. 22, 23 Interestingly, IL-9 overexpression caused an increase in intraepithelial mast cell numbers in the airways. 21 IL-9 genetic deletion was associated with an inability to increase mast cell numbers in the airways. 22 We observed increased intraepithelial mast cell numbers in ST2 KO mice. This increase was abrogated by the anti-TSLP intervention. We believe that the anti-TSLP-induced reduction in IL-9 levels led to a decrease in mast cell numbers and resolution of experimental asthma.
As noted above, ST2 KO mice produced variable results for experimental asthma.
12-17 Most of the previously described models involved an acute form of experimental asthma, which is different from our model. Our model is closer to that described by Iijima et al 13 and Vannella et al. 17 Both studies applied chronic exposure to a single allergen 17 or multiple allergens. 13 However, the foregoing studies analyzed experimental outcomes 24 hours after the last allergen exposure, which is different from our model because we analyzed outcomes 3 weeks after the last allergen exposure. The Vannella study outcomes are similar to those of our study. The Iijima study did report a significant reduction in airway eosinophil numbers and hyperreactivity. It should be noted that although it decreased statistically, airway hyperreactivity remained highly increased in ST2 KO mice in the Iijima study. ST2 KO mice had a significant reduction in IL-5 1 ILC2s. In accordance, BAL fluid eosinophil counts were also reduced in ST2 KO mice, which is similar to what was seen in the Iijima study. This is also in line with previous publications that demonstrated a pivotal role for the IL-33/ST2 axis in generation of IL-5 1 memory T H 2 cells 4 and production of IL-5 in allergic inflammation. 41 The lack of IL-5 1 but not IL-13 1 ILC2s in ST2 KO mice also suggests that production of IL-5 and IL-13 can be discordant under certain circumstances. This is not uncommon in the clinical setting because eosinophilia is not always associated with asthma and vice versa. The effect of ST2 deletion had a differential effect on BAL fluid leukocytes and tissue inflammation scores. ST2 KO mice had reduced eosinophil and neutrophil numbers in BAL fluid but increased total cell and macrophage numbers. The increase in numbers of BAL fluid macrophages is likely due to heightened levels of TSLP because the latter has been shown to stimulate extramedullary hematopoiesis and macrophage differentiation. 42 This mixed effect of ST2 deletion on BAL fluid leukocytes mirrored the effect on airway tissue, which showed inhibition of perivascular but not peribronchial inflammation.
In aggregate, our results suggest that the IL-33/ST2 pathway is important for eosinophilic inflammation but redundant for airway hyperreactivity and mucus production. The combined action of IL-33 and TSLP is essential for maintenance of airway hyperreactivity and goblet cell metaplasia during the chronic phase of experimental asthma. Because ST2 deletion has a mixed outcome in acute asthma, additional work is needed to more fully define how the pathogenesis of allergic lung disease differs between acute and chronic contexts. 
